sur Exyte
Exyte Successfully Integrates Pharmaplan to Boost Biopharma Engineering Capabilities
Exyte has completed the integration of Pharmaplan, unifying biopharma engineering capabilities within its European operations. The acquisition, announced in September 2024, aims to strengthen Exyte's position in the biotechnology and pharmaceutical sectors across Europe. This integrated setup has resulted in increased client demand and record order-intake levels in 2025.
The integration marks a significant milestone for Exyte, expanding its Life Sciences services to over 40 locations in 12 countries. Exyte now offers end-to-end EPC/EPCM services, from feasibility studies to compliant handover, in major life sciences markets.
With a global network of experts and digital engineering capabilities, Exyte maintains its competitive advantage. It combines a history of expertise in GMP environments with modern digital tools to deliver complex projects efficiently and reliably. The company's methods emphasize speed, regulatory compliance, and sustainability, catering to evolving industry trends.
R. H.
Copyright © 2025 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Exyte